Lanthio Pharma is a Dutch biopharmaceutical company focused on discovering and developing therapeutic peptides for severe diseases with high unmet medical need. The company operates in the biopharmaceutical market, primarily targeting oncology and critical care medicine. Utilizing proprietary lanthionine-constrained peptide technology, Lanthio Pharma creates peptides with superior target selectivity and stability. These peptides are designed to interact specifically with certain receptors, making them highly effective for therapeutic use. The company's business model revolves around research and development, clinical trials, and eventual commercialization of these therapeutic peptides. Revenue is generated through partnerships, licensing agreements, and government grants. Lanthio Pharma serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies.

Keywords: biopharmaceutical, therapeutic peptides, oncology, critical care, lanthionine-constrained, target selectivity, stability, clinical trials, healthcare, research.